ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China
May 07, 2025Everest Medicines announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). -
Calliditas Therapeutics signs agreement with Everest Medicines to develop and commercialize Nefecon
June 10, 2019Calliditas Therapeutics AB (“Calliditas”) and Everest Medicines II Limited (“Everest Medicines”) announced that they have entered into a license agreement to develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapo
Pharma Sources Insight January 2025
